Forensic Analysis · Healthcare / Pharmaceuticals / Biotech
ELI LILLY AND COMPANY (LLY)
A forensic read on ELI LILLY AND COMPANY built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
78 · Buy
Rating (0–100)
39.1
P / E
$979.6B
Market cap
0.63%
Dividend yield
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products, with a current focus on cardiometabolic health, oncology, immunology, and neuroscience. The company has shown remarkable financial acceleration, with revenue growing from $34.12B in FY2023 to $65.18B in FY2025, while net margin expanded from 15.4% to 31.7% over the same period.
The full forensic report — free
🔒Every red flag on LLY, detailed and traced to the filing
🔒Altman Z distress & Beneish M earnings-quality screens
🔒Calibrated 12-month price forecast + reverse-DCF
🔒Earnings-quality & capital-allocation forensics
No credit card · informational only, not investment advice
← Browse all forensic stock analyses
Data from SEC EDGAR public filings. Forensic signals flag probability, not certainty.